MOBIX LABS, INC short interest in 2025
In 2025, MOBIX LABS, INC's disclosed short interest ran from 0.22% of shares outstanding on 15 Jan 2025 to 1.50% on 31 Dec 2025, a change of +1.28 percentage points. The year's high was 3.15% on 14 Mar 2025 and its low 0.22% on 15 Jan 2025, averaging 1.62% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.44 days on 31 Mar 2025. Full history: MOBIX LABS, INC.
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 0.22% (15 Jan 2025)
- End of year
- 1.50% (31 Dec 2025)
- Change
- +1.28 pp
- High
- 3.15% (14 Mar 2025)
- Low
- 0.22% (15 Jan 2025)
- Average
- 1.62%
- Highest days to cover
- 5.44 (31 Mar 2025)
- SEC filings marked
- 5
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 0.22% | 1.00 | |
| 31 Jan 2025 | 2.82% | 1.00 | |
| 14 Feb 2025 | 2.79% | 2.03 | 10-Q filed |
| 28 Feb 2025 | 3.14% | 4.62 | results (8-K) |
| 14 Mar 2025 | 3.15% | 4.89 | |
| 31 Mar 2025 | 2.39% | 5.44 | |
| 15 Apr 2025 | 1.69% | 4.16 | |
| 30 Apr 2025 | 1.54% | 5.40 | |
| 15 May 2025 | 0.59% | 2.45 | 10-Q filed |
| 30 May 2025 | 0.57% | 1.67 | |
| 13 Jun 2025 | 0.35% | 1.06 | |
| 15 Jul 2025 | 0.68% | 2.27 | |
| 31 Jul 2025 | 0.89% | 1.00 | |
| 15 Aug 2025 | 0.79% | 2.02 | 10-Q filed |
| 29 Aug 2025 | 1.41% | 1.00 | |
| 15 Sep 2025 | 1.03% | 1.00 | |
| 30 Sep 2025 | 1.12% | 1.05 | |
| 15 Oct 2025 | 1.30% | 1.00 | |
| 31 Oct 2025 | 1.87% | 1.00 | |
| 14 Nov 2025 | 2.93% | 1.00 | |
| 28 Nov 2025 | 2.05% | 1.32 | |
| 15 Dec 2025 | 2.42% | 1.65 | results (8-K) |
| 31 Dec 2025 | 1.50% | 1.00 |
See also: MOBIX LABS, INC's full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.